Anticoagulation, Bleeding, Mortality, and Pathology in Hospi
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Thromboembolic disease is common in COVID-19. There is limited evidence on the association of in-hospital anticoagulation (AC) with outcomes and postmortem findings.

The purpose of this study was to examine association of AC with in-hospital outcomes and describe thromboembolic findings on autopsies.

This retrospective analysis examined the association of AC with mortality, intubation, and major bleeding. Subanalyses were also conducted on the association of therapeutic versus prophylactic AC initiated less than 48 h from admission. Thromboembolic disease was contextualized by premortem AC among consecutive autopsies.

-- Among 4,389 patients, median age was 65 years with 44% women. Compared with no AC, therapeutic AC and prophylactic AC were associated with lower in-hospital mortality and intubation.

-- When initiated less than 48 h from admission, there was no statistically significant difference between therapeutic (n = 766) versus prophylactic AC.

-- Overall, 89 patients (2%) had major bleeding adjudicated by clinician review, with 27 of 900 (3.0%) on therapeutic, 33 of 1,959 (1.7%) on prophylactic, and 29 of 1,530 (1.9%) on no AC.

-- Of 26 autopsies, 11 (42%) had thromboembolic disease not clinically suspected and 3 of 11 (27%) were on therapeutic AC.

Conclusively, AC was associated with lower mortality and intubation among hospitalized COVID-19 patients. Compared with prophylactic AC, therapeutic AC was associated with lower mortality, although not statistically significant. Autopsies revealed frequent thromboembolic disease. These data may inform trials to determine optimal AC regimens.